Targeting CTLA-4 without colitis induction is gut microbiota dependent
Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 antibodies, are widely used in cancer immunotherapy. CTLA-4 blockers such as Yervoy (ipilimumab, Bristol Myers Squibb Co.) stimulate antitumoral immune responses, but may also induce toxicity, such as colitis, a common immune-related adverse event that can lead to treatment discontinuation.
Bristol Myers Squibb Co Immuno Oncology Bioworld Science Gut Microbiota Ctla 4 University Of Michigan
Source: bioworld.com